Tapper Amy E. 4

Accession 0001567619-22-021865

CIK 0001623715other

Filed

Dec 19, 7:00 PM ET

Accepted

Dec 20, 4:19 PM ET

Size

24.1 KB

Accession

0001567619-22-021865

Form 4

Period: 2022-12-16

See Remarks

Transactions

Exercise/Conversion
Common Stock
2022-12-16$2.27/sh+2,380$5,403→ 156,840 total
Exercise/Conversion
Stock Option (Right to buy)
2022-12-16−18,009→ 2,729 total
Exercise: $1.52Exp: 2029-04-09→ Common Stock (18,009 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2022-12-16−5,952→ 0 total
Exercise: $2.19From: 2019-11-17Exp: 2025-11-16→ Common Stock (5,952 underlying)
Exercise/Conversion
Common Stock
2022-12-16$1.52/sh+18,009$27,374→ 219,349 total
Exercise/Conversion
Stock Option (Right to buy)
2022-12-16−2,380→ 0 total
Exercise: $2.27From: 2020-11-09Exp: 2026-11-08→ Common Stock (2,380 underlying)
Exercise/Conversion
Stock Option (Right to buy)
2022-12-16−44,500→ 8,232 total
Exercise: $2.52From: 2021-01-01Exp: 2027-03-28→ Common Stock (44,500 underlying)
Exercise/Conversion
Common Stock
2022-12-16$2.10/sh+29,461$61,868→ 148,508 total
Exercise/Conversion
Common Stock
2022-12-16$2.19/sh+5,952$13,035→ 154,460 total
Exercise/Conversion
Common Stock
2022-12-16$2.52/sh+44,500$112,140→ 201,340 total
Sale
Common Stock
2022-12-16$35.78/sh−100,302$3,588,725→ 119,047 total
Exercise/Conversion
Stock Option (Right to buy)
2022-12-16−29,461→ 23,562 total
Exercise: $2.10Exp: 2030-09-09→ Common Stock (29,461 underlying)

Footnotes (3)

[F1]The transaction was executed in multiple trades in prices ranging from $35.77 to $35.79, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
[F2]The Option vests with respect to 25% of the shares subject thereto on July 7, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
[F3]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from April 10, 2019 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Documents

1 file

Imago BioSciences, Inc.

CIK 0001623715

Entity typeother